Results 161 to 170 of about 31,452 (261)

Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors. [PDF]

Front Immunol
Wu X, Li P, Li T, Fan Q, Wu H.
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Bispecific single-domain antibody (VHH) fused with human IgG1 Fc with dual specificity effectively neutralize Naja Kaouthia venom. [PDF]

PLoS Negl Trop Dis
Pothisamutyothin K, Sathorn S, Boonmee R, Thaveekarn W, Arunmanee W.   +4 more
europepmc   +1 more source

Periodontitis and Rheumatoid Arthritis—Mechanistic Evidence

Journal of Periodontal Research, EarlyView.
Periodontitis and rheumatoid arthritis are linked via the two‐hit model whereby early periodontal inflammation can lead to autoantibody production capable of interacting with inflamed synovial tissues. Subsequent systemic inflammation can exacerbate the periodontal inflammatory response and bacterial dysbiosis leading to further autoantibody production
Mark Bartold, Chia Wei Cheah, Rathna Devi Vaithilingam   +2 more
wiley   +1 more source

Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies. [PDF]

Front Immunol
Li J, Abulaiti A, Li D, Zhao Y, Wahafu P, Maimaitiming M, Qiu S, Zhang Y, An Y, Wang W, Shi L, Yakufu M, Shu L, Li G, Liu Z.   +14 more
europepmc   +1 more source

Development of Bispecific Antibody Targeting Human IL-17A and IL-6. [PDF]

Antibodies (Basel)
Pamuła B, Banach M, Mikońska M, Korytkowska K, Lacek K, Śniadała O, Marczak M, Flis K, Sowińska A, Kołakowski D, Pieczykolan J, Zygmunt B, Wieczorek M, Abramczyk O.   +13 more
europepmc   +1 more source

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, Volume 159, Issue 7, Page 1633-1641, 1 October 2026.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source

Improving Gallbladder Cancer Outcomes with Antibody-Based Therapies and Immunological Profiling: A Literature Review. [PDF]

Antibodies (Basel)
Caglevic C, Contreras-Torrez MA, Reyes-Cosmelli F, Uribe-Maturana R, Mahave M, Caire N, Villanueva-Olivares L, Cid F, Lladser A, Sapunar J.   +9 more
europepmc   +1 more source

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN)

American Journal of Hematology, Volume 101, Issue 9, Page 2353-2370, September 2026.
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W. C. J. van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson, Charlotte Pawlyn, María‐Victoria Mateos, Sonja Zweegman, Martin Schreder, Meral Beksaç, Christoph Driessen, Enrique M. Ocio, Rakesh Popat, Leo Rasche, Cyrille Touzeau, Pellegrino Musto, Annemiek Broijl, Meletios Dimopoulos, Roman Hajek, Mario Boccadoro, Pieter Sonneveld   +25 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source